BrainsWay (BWAY) vs Embecta (EMBC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BrainsWay (BWAY) has outperformed Embecta (EMBC) over the past year, gaining 13.9% versus a loss of 58.7%. BrainsWay is the larger company by market cap ($341.3 million vs $341.1 million), about 1.0 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 17.0x for BrainsWay).
Embecta pays a dividend yielding 7.64%, while BrainsWay does not currently pay one. Embecta converts more of its revenue into profit, with a net margin of 8.8% versus 7.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | EMBC |
|---|---|---|
| Share price | $8.48 | $6.02 |
| Market cap | $341.35M | $341.09M |
| 1-day change | -2.86% | -2.75% |
| YTD return | -10.83% | -49.33% |
| 1-year return | +13.90% | -58.68% |
| 5-year return | +130.75% | — |
| P/E ratio (TTM) | 35.33 | 4.10 |
| Forward P/E | 16.96 | 3.42 |
| EPS (TTM) | $0.24 | $1.47 |
| Dividend yield | 0.00% | 7.64% |
| Annual dividend | $0.00 | $0.46 |
| Revenue (latest FY) | $41.02M | $1.08B |
| Revenue growth (YoY) | +29.04% | -3.80% |
| Net income (latest FY) | $2.92M | $95.40M |
| Gross margin | 74.56% | 62.64% |
| Operating margin | 3.39% | 22.41% |
| Net margin | 7.12% | 8.83% |
| 52-week high | $17.40 | $14.78 |
| 52-week low | $7.30 | $2.77 |
| Distance from 52-week high | -51.26% | -59.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +127.24% | -33.55% |
| Average volume | 110.35K | 1.01M |
| Shares outstanding | 40.25M | 56.66M |
| Employees | 129 | 1,850 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BWAY has outperformed EMBC by 72.6 percentage points over the past year.
- BrainsWay trades at a higher earnings multiple (35.3x vs 4.1x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (7.64% vs 0.00%).
- BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs -3.80%).
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 129 employees
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
BWAY vs EMBC FAQ
Which is bigger, BrainsWay or Embecta?
BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $341.09M for Embecta (EMBC).
Which stock has performed better over the past year, BWAY or EMBC?
BWAY returned +13.90% over the past 12 months, compared with -58.68% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BWAY or EMBC?
EMBC has the lower trailing P/E at 4.1, versus 35.3 for BWAY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BrainsWay or Embecta?
Embecta pays a dividend yielding 7.64%, while BrainsWay does not currently pay a regular dividend.
Are BrainsWay and Embecta in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.